Request for Question Clarification by
knowledge_seeker-ga
on
29 Oct 2002 08:39 PST
Hi svannes,
There is an online database of over 6700 clinical trials being
conducted in the US and overseas (80% US). This database allows you
to browse condition or sponsor or search based on keywords (ie. Drug
name, trial locations, condition etc).
Here is a sample record from that database (Ive cut some sections for
the sake of brevity but have labelled them so you know whats missing)
--
-------------------------------------
Combination Therapy with Avonex and BiMonthly High Dose Intravenous
Methotrexate in Multiple Sclerosis
This study is currently recruiting patients.
Sponsored by:
MidAmerica Neuroscience Institute
Consultants in Neurology, PC
MidAmerica Neuroscience Research Foundation
Biogen
Purpose :
The participant will receive weekly intramuscular treatment with
AVONEX® (interferon beta 1-a) and bi-monthly high dose intravenous
methotrexate with Leucovorin rescue.
Condition - Multiple Sclerosis
Treatment or Intervention -- Drug: interferon beta 1a ; Drug:
methotrexate
Phase: Phase IV
MEDLINEplus related topics: Multiple Sclerosis
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control,
Single Group Assignment, Safety/Efficacy Study
Official Title: An Open Label Study of the Safety and Efficacy of
Combination Therapy with AVONEX and Bi-Monthly High Dose Intravenous
Methotrexate with Leucovorin Rescue in the Treatment of Multiple
Sclerosis
Further Study Details:
The participant will receive weekly intramuscular treatment with
AVONEX® (interferon beta 1-a) and bi-monthly high dose intravenous
methotrexate with Leucovorin rescue
[cut 3 long paragraphs of study
description]
Eligibility
Ages Eligible for Study: 18 Years - 60 Years,
Genders Eligible for Study: Both
Criteria :
To be eligible for entry into this study, candidates must meet the
following eligibility criteria at the time of enrollment:
Between the ages of 18 and 60 years, inclusive.
Diagnosis of clinically definite relapsing MS.
Must have been on AVONEX® therapy for at least six months.
Brain MRI scans demonstrating lesions consistent with MS.
[cut long paragraph of criteria description]
Expected Total Enrollment: 15
Location and Contact Information
Missouri
MidAmerica Neuroscience Institute, Kansas City, Missouri, 64108,
United States; Recruiting
Laurie A Dressman, RN, BA 816-753-8800 Ext. 124 ldressman@cinpc.com
John A Hunter, PsyD 816-753-8800 Ext. 145 jhunter@cinpc.com
Vernon D Rowe, MD, Principal Investigator
More Information
Study ID Numbers MANI-MTX01-001
Date study started July 2001
Record last reviewed May 2002
NLM Identifier NCT00037102
---------------------------------
This appears to me to be the same information that is a available
through the biospace.com subscription. If so, would you like me to
post an answer with a link to this database? If not, maybe you can
clarify why it doesnt meet your needs. Thanks
-K~